GDNF Gene Therapy for Parkinson's Disease

Open to people ages 35-75

• Male and female adults 35-75 years of age (inclusive)
• Diagnosed with Parkinson's disease
• Modified Hoehn and Yahr stage I-III OFF medication
• Time since receiving a clinical diagnosis of PD and disease severity consistent with one of the following:
• EITHER: Less than 5 years since clinical diagnosis of PD and mild to moderate UPDRS III OFF score
• OR: At least 4 years since clinical diagnosis of PD and moderate to severe UPDRS III OFF score
• Responsiveness to levodopa

• Atypical parkinsonism
• Severe dyskinesia
• Presence of dementia, psychosis, substance abuse or qualify as "severe depression"
• Prior brain surgery (i.e. deep brain stimulator or DBS implantation) or other brain imaging abnormalities
• Receiving an investigational drug
• History of cancer or poorly controlled medical conditions that would increase surgical risk
• Inability to tolerate laying flat in an MRI or allergy to gadolinium